Sanuwave Health Inc (SNWV) 0.1240 $SNWV
SANUWAVE Health Reports Record Year to Date Order Book for orthoPACE and dermaPACE - Up 280% Over 2015
GlobeNewswire - 1 hr 6 mins ago
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported a record order book for the 2016 year with 45 firm orders for the Company's orthoPACE and dermaPACE Systems. This is up 280% from the 16 total orders for the same systems in all of 2015 primarily due to strong interest in international markets, notably South Korea and Italy. The Company is continuing to work with our various distributors to further improve this record pace for 2016. The outlook for 2017 is expected to be even stronger than 2016, with the company anticipating FDA approval in the first quarter of 2017 of the de novo petition filed for dermaPACE for the treatment of diabetic foot ulcers.
SANUWAVE Health Reports Second Quarter Financial Results and Provides a Business Update
GlobeNewswire - Mon Aug 15, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three and six months ended June 30, 2016 and provided a business update. The Company will host a conference call at 11AM Eastern Time today.
SANUWAVE Health Submits de novo Petition for FDA Review and Classification of the dermaPACE System to Treat Diabetic Foot Ulcers
GlobeNewswire - Thu Aug 11, 1:00PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a de novo petition requesting Agency review and classification of the dermaPACE System for treating Diabetic Foot Ulcers (DFU) as a Class II device. Through the course of two trials, 336 patients were randomized in double-blind, parallel group, sham controlled, multicenter, 24-week pivotal clinical trials that were designed to quantify the safety and effectiveness of the noninvasive procedures with the dermaPACE System (dermaPACE(R)).
Sanuwave Health Announces Second Amendment and Extension of Promissory Notes
GlobeNewswire - Fri Aug 05, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced it has entered into a second amendment to certain provisions of the two promissory notes dated August 1, 2005 between the Company and HealthTronics, Inc. with an aggregate outstanding principal balance of $5,372,743.
SANUWAVE Health to Hold Second Quarter 2016 Financial Results and Business Update Call on Monday, August 15, 2016
GlobeNewswire - Mon Aug 01, 3:46PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release financial results for the second quarter ended June 30, 2016, on August 15, 2016.
SANUWAVE Health Reports First Quarter Financial Results and Provides a Business Update
GlobeNewswire - Tue May 17, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), reported financial results for the three months ended March 31, 2016 and provided a business update on Monday, May 16, 2016.
SANUWAVE Health to Hold First Quarter 2016 Financial Results and Business Update Call on Monday, MAY 16, 2016
GlobeNewswire - Fri May 06, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) announced today that the Company will release financial results for the first quarter ended March 31, 2016, after the markets close on May 13, 2016.
SANUWAVE Health Appoints Orthopaedic and Podiatric Shockwave Executive, A. Michael Stolarski, to its Board
GlobeNewswire - Tue Apr 19, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the appointment of A. Michael Stolarski to the Company's Board of Directors. Mr. Stolarski has 20 years of experience at multiple levels in the orthopedic, podiatric and urologic shockwave market, including positions within business development and finance. With this appointment, the Company's Board has four members.
SANUWAVE Health Reports 2015 Financial Results and Provides a Business Update
GlobeNewswire - Wed Mar 30, 4:15PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV), today reported financial results for the year ended December 31, 2015 and provided a business update. The Company will host a conference call tomorrow, March 31, 2016, at 10:00 a.m. Eastern Time.
SANUWAVE Receives U.S. Patent for Novel Electrode Design to Increase Useful Life of Electrohydraulic Shock Wave Devices
GlobeNewswire - Tue Mar 29, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV), announced today the receipt of U.S. Patent number 9,198,825 from the U.S. Patent and Trademark Office entitled "Increase Electrode Life in Devices Used for Extracorporeal Shockwave Therapy (ESWT)". This patent has a patent life to July 2033.
SANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers
GlobeNewswire - Thu Mar 24, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) (www.sanuwave.com), today announced positive combined 24-week data from the Company's pivotal double-blinded, randomized Phase III, Investigational Device Exemption (IDE) clinical trials comparing dermaPACE to Sham-control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers. Diabetic foot ulcers are an area of significant unmet medical need and represent a $2 billion market in the U.S. alone.
SANUWAVE Health Provides Positive Fourth Quarter Business Update
GlobeNewswire - Tue Dec 15, 10:00AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) today reported positive business developments leading to a strong outlook for its fourth quarter ending December 31, 2015.
SANUWAVE Health names Lisa Sundstrom as CFO
M2 - Tue Dec 15, 6:15AM CST
Shock wave technology company SANUWAVE Health (OTCBB:SNWV) reported on Monday that it has appointed Lisa Sundstrom as its new chief financial officer.
SANUWAVE Health Appoints Lisa Sundstrom as Chief Financial Officer
GlobeNewswire - Mon Dec 14, 10:00AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading shock wave technology company, today announced that Lisa Sundstrom, 46, has been promoted to Chief Financial Officer. Ms. Sundstrom, was formerly interim Chief Financial Officer as of July 2015.
OxySure (OXYS) Launches OxyTrac(TM) to Save Lives & Help Companies Stay Compliant
ACCESSWIRE - Thu Dec 10, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 10, 2015 / Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.
SMED: 4.62 (-0.06), BMRA: 2.82 (-0.15)
SANUWAVE Health Reports Third Quarter Financial Results and Provides a Business Update
GlobeNewswire - Thu Nov 12, 4:05PM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three and nine months ended September 30, 2015 and provided a business update. The Company will host a conference call tomorrow, Friday, November 13, 2015, at 11:00 a.m. Eastern Time.
SANUWAVE Health to Hold Third Quarter 2015 Financial Results and Business Update Call on Friday, November 13, 2015
GlobeNewswire - Thu Nov 05, 7:30AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2015, after the markets close on November 12, 2015.
SANUWAVE Health to Present at the 2015 SEETHRUEQUITY Microcap Investor Forum
GlobeNewswire - Tue Nov 03, 7:30AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), a shockwave technology company, announced today that Kevin A. Richardson II, SANUWAVE's Chairman of the board and Chief Executive Officer, and Lisa Sundstrom, SANUWAVE's Interim Chief Financial Officer, will present at the 2015 SeeThruEquity Microcap Investor Forum, being held Thursday, November 12, 2015 at Convene Grand Central in New York City.
SANUWAVE Health Releases dermaPACE Clinical Trial Top Line Data and Preliminary Data Analysis Results
GlobeNewswire - Thu Oct 08, 7:02AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced top line and preliminary data analysis from the Company's pivotal Phase III, Investigational Device Exemption (IDE) supplemental clinical trial comparing the rates of 100% wound closure at 12 weeks between dermaPACE and Sham control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers (DFUs). This study supplemented the Company's earlier 206 patient Phase III trial of identical endpoints which demonstrated the exceptional safety profile and clinical benefit of the dermaPACE device for the treatment of diabetic foot ulcers; an area of significant unmet medical need and represents a $2 billion market in the United States alone.
SANUWAVE Health to Present at the 2015 Aegis Growth Conference
GlobeNewswire - Thu Oct 01, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), a shockwave technology company, announced today that Kevin A. Richardson II, SANUWAVE's Chairman of the board and Chief Executive Officer, and Lisa Sundstrom, SANUWAVE's Interim Chief Financial Officer, will present at the 2015 Aegis Growth Conference, being held Wednesday, October 7, 2015 through Friday, October 9, 2015 at the Encore at Wynn Las Vegas, Las Vegas, Nevada.
SANUWAVE Health Reports Record Year to Date Order Book for orthoPACE and dermaPACE - Up 280% Over 2015
GlobeNewswire - 1 hr 6 mins ago
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported a record order book for the 2016 year with 45 firm orders for the Company's orthoPACE and dermaPACE Systems. This is up 280% from the 16 total orders for the same systems in all of 2015 primarily due to strong interest in international markets, notably South Korea and Italy. The Company is continuing to work with our various distributors to further improve this record pace for 2016. The outlook for 2017 is expected to be even stronger than 2016, with the company anticipating FDA approval in the first quarter of 2017 of the de novo petition filed for dermaPACE for the treatment of diabetic foot ulcers.
SANUWAVE Health Reports Second Quarter Financial Results and Provides a Business Update
GlobeNewswire - Mon Aug 15, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three and six months ended June 30, 2016 and provided a business update. The Company will host a conference call at 11AM Eastern Time today.
SANUWAVE Health Submits de novo Petition for FDA Review and Classification of the dermaPACE System to Treat Diabetic Foot Ulcers
GlobeNewswire - Thu Aug 11, 1:00PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a de novo petition requesting Agency review and classification of the dermaPACE System for treating Diabetic Foot Ulcers (DFU) as a Class II device. Through the course of two trials, 336 patients were randomized in double-blind, parallel group, sham controlled, multicenter, 24-week pivotal clinical trials that were designed to quantify the safety and effectiveness of the noninvasive procedures with the dermaPACE System (dermaPACE(R)).
Sanuwave Health Announces Second Amendment and Extension of Promissory Notes
GlobeNewswire - Fri Aug 05, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced it has entered into a second amendment to certain provisions of the two promissory notes dated August 1, 2005 between the Company and HealthTronics, Inc. with an aggregate outstanding principal balance of $5,372,743.
SANUWAVE Health to Hold Second Quarter 2016 Financial Results and Business Update Call on Monday, August 15, 2016
GlobeNewswire - Mon Aug 01, 3:46PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release financial results for the second quarter ended June 30, 2016, on August 15, 2016.
SANUWAVE Health Reports First Quarter Financial Results and Provides a Business Update
GlobeNewswire - Tue May 17, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), reported financial results for the three months ended March 31, 2016 and provided a business update on Monday, May 16, 2016.
SANUWAVE Health to Hold First Quarter 2016 Financial Results and Business Update Call on Monday, MAY 16, 2016
GlobeNewswire - Fri May 06, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) announced today that the Company will release financial results for the first quarter ended March 31, 2016, after the markets close on May 13, 2016.
SANUWAVE Health Appoints Orthopaedic and Podiatric Shockwave Executive, A. Michael Stolarski, to its Board
GlobeNewswire - Tue Apr 19, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced the appointment of A. Michael Stolarski to the Company's Board of Directors. Mr. Stolarski has 20 years of experience at multiple levels in the orthopedic, podiatric and urologic shockwave market, including positions within business development and finance. With this appointment, the Company's Board has four members.
SANUWAVE Health Reports 2015 Financial Results and Provides a Business Update
GlobeNewswire - Wed Mar 30, 4:15PM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV), today reported financial results for the year ended December 31, 2015 and provided a business update. The Company will host a conference call tomorrow, March 31, 2016, at 10:00 a.m. Eastern Time.
SANUWAVE Receives U.S. Patent for Novel Electrode Design to Increase Useful Life of Electrohydraulic Shock Wave Devices
GlobeNewswire - Tue Mar 29, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV), announced today the receipt of U.S. Patent number 9,198,825 from the U.S. Patent and Trademark Office entitled "Increase Electrode Life in Devices Used for Extracorporeal Shockwave Therapy (ESWT)". This patent has a patent life to July 2033.
SANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot Ulcers
GlobeNewswire - Thu Mar 24, 8:00AM CDT
SANUWAVE Health, Inc. (OTCBB:SNWV) (www.sanuwave.com), today announced positive combined 24-week data from the Company's pivotal double-blinded, randomized Phase III, Investigational Device Exemption (IDE) clinical trials comparing dermaPACE to Sham-control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers. Diabetic foot ulcers are an area of significant unmet medical need and represent a $2 billion market in the U.S. alone.
SANUWAVE Health Provides Positive Fourth Quarter Business Update
GlobeNewswire - Tue Dec 15, 10:00AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) today reported positive business developments leading to a strong outlook for its fourth quarter ending December 31, 2015.
SANUWAVE Health names Lisa Sundstrom as CFO
M2 - Tue Dec 15, 6:15AM CST
Shock wave technology company SANUWAVE Health (OTCBB:SNWV) reported on Monday that it has appointed Lisa Sundstrom as its new chief financial officer.
SANUWAVE Health Appoints Lisa Sundstrom as Chief Financial Officer
GlobeNewswire - Mon Dec 14, 10:00AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading shock wave technology company, today announced that Lisa Sundstrom, 46, has been promoted to Chief Financial Officer. Ms. Sundstrom, was formerly interim Chief Financial Officer as of July 2015.
OxySure (OXYS) Launches OxyTrac(TM) to Save Lives & Help Companies Stay Compliant
ACCESSWIRE - Thu Dec 10, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / December 10, 2015 / Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.
SMED: 4.62 (-0.06), BMRA: 2.82 (-0.15)
SANUWAVE Health Reports Third Quarter Financial Results and Provides a Business Update
GlobeNewswire - Thu Nov 12, 4:05PM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three and nine months ended September 30, 2015 and provided a business update. The Company will host a conference call tomorrow, Friday, November 13, 2015, at 11:00 a.m. Eastern Time.
SANUWAVE Health to Hold Third Quarter 2015 Financial Results and Business Update Call on Friday, November 13, 2015
GlobeNewswire - Thu Nov 05, 7:30AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2015, after the markets close on November 12, 2015.
SANUWAVE Health to Present at the 2015 SEETHRUEQUITY Microcap Investor Forum
GlobeNewswire - Tue Nov 03, 7:30AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV), a shockwave technology company, announced today that Kevin A. Richardson II, SANUWAVE's Chairman of the board and Chief Executive Officer, and Lisa Sundstrom, SANUWAVE's Interim Chief Financial Officer, will present at the 2015 SeeThruEquity Microcap Investor Forum, being held Thursday, November 12, 2015 at Convene Grand Central in New York City.
SANUWAVE Health Releases dermaPACE Clinical Trial Top Line Data and Preliminary Data Analysis Results
GlobeNewswire - Thu Oct 08, 7:02AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced top line and preliminary data analysis from the Company's pivotal Phase III, Investigational Device Exemption (IDE) supplemental clinical trial comparing the rates of 100% wound closure at 12 weeks between dermaPACE and Sham control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers (DFUs). This study supplemented the Company's earlier 206 patient Phase III trial of identical endpoints which demonstrated the exceptional safety profile and clinical benefit of the dermaPACE device for the treatment of diabetic foot ulcers; an area of significant unmet medical need and represents a $2 billion market in the United States alone.
SANUWAVE Health to Present at the 2015 Aegis Growth Conference
GlobeNewswire - Thu Oct 01, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), a shockwave technology company, announced today that Kevin A. Richardson II, SANUWAVE's Chairman of the board and Chief Executive Officer, and Lisa Sundstrom, SANUWAVE's Interim Chief Financial Officer, will present at the 2015 Aegis Growth Conference, being held Wednesday, October 7, 2015 through Friday, October 9, 2015 at the Encore at Wynn Las Vegas, Las Vegas, Nevada.
